164 related articles for article (PubMed ID: 28428557)
1. The prognostic significance of Cdc6 and Cdt1 in breast cancer.
Mahadevappa R; Neves H; Yuen SM; Bai Y; McCrudden CM; Yuen HF; Wen Q; Zhang SD; Kwok HF
Sci Rep; 2017 Apr; 7(1):985. PubMed ID: 28428557
[TBL] [Abstract][Full Text] [Related]
2. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
4. In Vivo DNA Re-replication Elicits Lethal Tissue Dysplasias.
Muñoz S; Búa S; Rodríguez-Acebes S; Megías D; Ortega S; de Martino A; Méndez J
Cell Rep; 2017 May; 19(5):928-938. PubMed ID: 28467906
[TBL] [Abstract][Full Text] [Related]
5. Redundant and differential regulation of multiple licensing factors ensures prevention of re-replication in normal human cells.
Sugimoto N; Yoshida K; Tatsumi Y; Yugawa T; Narisawa-Saito M; Waga S; Kiyono T; Fujita M
J Cell Sci; 2009 Apr; 122(Pt 8):1184-91. PubMed ID: 19339550
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer.
Zhang X; Xiao D; Wang Z; Zou Y; Huang L; Lin W; Deng Q; Pan H; Zhou J; Liang C; He J
Mol Cancer Res; 2014 Nov; 12(11):1535-46. PubMed ID: 25100863
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
8. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
9. mRNA expression of the DNA replication-initiation proteins in epithelial dysplasia and squamous cell carcinoma of the tongue.
Li JN; Feng CJ; Lu YJ; Li HJ; Tu Z; Liao GQ; Liang C
BMC Cancer; 2008 Dec; 8():395. PubMed ID: 19116018
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells.
Liu Y; Gong Z; Sun L; Li X
Biochim Biophys Acta; 2014; 1839(4):297-305. PubMed ID: 24583551
[TBL] [Abstract][Full Text] [Related]
11. CUL4A Ubiquitin Ligase Is an Independent Predictor of Overall Survival in Pancreatic Adenocarcinoma.
Tavlas P; Nikou S; Geramoutsou C; Bosgana P; Tsaniras SC; Melachrinou M; Maroulis I; Bravou V
Cancer Genomics Proteomics; 2024; 21(2):166-177. PubMed ID: 38423594
[TBL] [Abstract][Full Text] [Related]
12. Sequential ATP hydrolysis by Cdc6 and ORC directs loading of the Mcm2-7 helicase.
Randell JC; Bowers JL; Rodríguez HK; Bell SP
Mol Cell; 2006 Jan; 21(1):29-39. PubMed ID: 16387651
[TBL] [Abstract][Full Text] [Related]
13. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
14. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
[TBL] [Abstract][Full Text] [Related]
15. SPOP is essential for DNA replication licensing through maintaining translation of CDT1 and CDC6 in HaCaT cells.
Sanada S; Maekawa M; Tate S; Nakaoka H; Fujisawa Y; Sayama K; Higashiyama S
Biochem Biophys Res Commun; 2023 Apr; 651():30-38. PubMed ID: 36791496
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Alkner S; Jensen MB; Rasmussen BB; Bendahl PO; Fernö M; Rydén L; Mouridsen H;
Breast Cancer Res Treat; 2017 Nov; 166(2):481-490. PubMed ID: 28766132
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
[TBL] [Abstract][Full Text] [Related]
18. PIP-box-mediated degradation prohibits re-accumulation of Cdc6 during S phase.
Clijsters L; Wolthuis R
J Cell Sci; 2014 Mar; 127(Pt 6):1336-45. PubMed ID: 24434580
[TBL] [Abstract][Full Text] [Related]
19. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
20. mTOR Signaling Upregulates CDC6 via Suppressing miR-3178 and Promotes the Loading of DNA Replication Helicase.
Wu X; Li S; Hu X; Xiang X; Halloran M; Yang L; Williams TM; Houghton PJ; Shen C; He Z
Sci Rep; 2019 Jul; 9(1):9805. PubMed ID: 31285446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
